Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
- PMID: 33896013
- PMCID: PMC9291745
- DOI: 10.1002/jimd.12392
Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model
Abstract
Phenylketonuria (PKU) is the most common inborn error of metabolism of the liver, and results from mutations of both alleles of the phenylalanine hydroxylase gene (PAH). As such, it is a suitable target for gene therapy via gene delivery with a recombinant adeno-associated virus (AAV) vector. Here we use the synthetic AAV vector Anc80 via systemic administration to deliver a functional copy of a codon-optimized human PAH gene, with or without an intron spacer, to the Pahenu2 mouse model of PKU. Dose-dependent transduction of the liver and expression of PAH mRNA were present with both vectors, resulting in significant and durable reduction of circulating phenylalanine, reaching near control levels in males. Coat color of treated Pahenu2 mice reflected an increase in pigmentation from brown to the black color of control animals, further indicating functional restoration of phenylalanine metabolism and its byproduct melanin. There were no adverse effects associated with administration of AAV up to 5 × 1012 VG/kg, the highest dose tested. Only minor and/or transient variations in some liver enzymes were observed in some of the AAV-dosed animals which were not associated with pathology findings in the liver. Finally, there was no impact on cell turnover or apoptosis as evaluated by Ki-67 and TUNEL staining, further supporting the safety of this approach. This study demonstrates the therapeutic potential of AAV Anc80 to safely and durably cure PKU in a mouse model, supporting development for clinical consideration.
Keywords: Anc80; adeno-associated virus (AAV) vector; gene therapy; inborn error of metabolism; phenylketonuria.
© 2021 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Conflict of interest statement
N. D. W., L. T. M., A. D., and G. G. A. are employees of Vivet Therapeutics, which funded the study.
Figures
References
-
- Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417‐1427. - PubMed
-
- Scriver CR, Waters PJ. Monogenic traits are not simple: lessons from phenylketonuria. Trends Genet. 1999;15:267‐272. - PubMed
-
- Christ SE, Huijbregts SC, de Sonneville LM, White DA. Executive function in early‐treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab. 2010;99(Suppl 1):S22‐S32. - PubMed
-
- Mochizuki S, Mizukami H, Ogura T, et al. Long‐term correction of hyperphenylalaninemia by AAV‐mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther. 2004;11:1081‐1086. - PubMed
-
- Ding Z, Georgiev P, Thony B. Administration‐route and gender‐independent long‐term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno‐associated virus 8 pseudotyped vector‐mediated gene transfer. Gene Ther. 2006;13:587‐593. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
